RAP is in a class of it's own in terms of tech and share price appreciation.
But there is no doubt RAP has paved the way for ePAT.
RAP has also educated the market on this vertical which is important. And while they are different companies, the story and process to commercialisation is similar.
RAP and ePAT are in the MedTech sweet-spot IMO. Technology with implementations beyond hospitals seem to be doing well as hospital based technology becomes an extremely competitive space with long lead times and roadblocks (red tape) for progress.
The demand for NeuroTech (another MedTech listing coming up) reaffirms the markets are loving this space.
ePAT also has a large global market from what i have read, and a number of creditable third parties looking to start implementation studies (BUPA, Mercy Place).
Could blossom into something decent here. Too early to tell but at this market cap worth the punt IMO.
